OPKO Health, Inc. is a multinational healthcare company that operates in the diagnostics and pharmaceuticals sectors. Its Diagnostics segment includes BioReference Laboratories, which provides a range of laboratory testing services, including core genetic testing and the 4Kscore prostate cancer test. The Pharmaceuticals segment offers several treatments, including Rayaldee for secondary hyperparathyroidism, and is developing drugs such as OPK88004, a selective androgen receptor modulator, and OPK88003 for type 2 diabetes and obesity. Additionally, OPKO is advancing hGH-CTP, a once-weekly human growth hormone injection, and has various products targeting chemotherapy-induced nausea, hemophilia, and other medical conditions. The company also engages in the development and commercialization of specialty active pharmaceutical ingredients and a range of pharmaceutical, nutraceutical, and veterinary products. With operations spanning countries such as Ireland, Chile, Spain, and Mexico, OPKO Health focuses on leveraging its proprietary technologies and expertise to grow in key medical markets. Headquartered in Miami, Florida, OPKO Health was incorporated in 1991.
ModeX Therapeutics is a manufacturer and developer of immune therapy drugs.
HealthSnap
Venture Round in 2021
HealthSnap, Inc. is a healthcare technology company that specializes in developing solutions for processing patient lifestyle data to enhance healthcare delivery. Incorporated in 2015 and headquartered in Miami, Florida, with an additional office in San Mateo, California, HealthSnap offers a comprehensive Virtual Care Management Platform. This platform integrates various services, including Remote Patient Monitoring (RPM) and Chronic Care Management (CCM), to assist healthcare organizations in improving patient outcomes, reducing healthcare utilization, and diversifying revenue streams. By utilizing data from wearables, remote sensors, and patient questionnaires, HealthSnap's platform enables effective care coordination and automated management of chronic conditions, empowering clinicians with the necessary tools to prevent and manage lifestyle-related diseases efficiently.
VBI Vaccines
Post in 2017
VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.
Eloxx
Series C in 2017
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.
Phio Pharmaceuticals
Post in 2016
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company based in Marlborough, Massachusetts, focusing on the development of immuno-oncology therapeutics. The company utilizes its proprietary INTASYL technology platform, which enables the creation of self-delivering RNA interference (RNAi) therapies aimed at enhancing the immune system's ability to combat cancer. Phio's lead therapeutic candidates include PH-762, targeting the PD-1 checkpoint protein, PH-804, which addresses the TIGIT receptor on immune cells, and PH-790, aimed at the PD-L1 protein that inhibits immune response. These compounds are designed to silence genes that tumors exploit to evade immune detection, thus improving the effectiveness of adoptive cell transfer therapies. Phio Pharmaceuticals has established collaborations with notable institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München. The company was originally incorporated in 2011 under the name RXi Pharmaceuticals Corporation, which was changed to Phio Pharmaceuticals in November 2018.
Transition Therapeutics
Acquisition in 2016
Transition Therapeutics Inc. is a biopharmaceutical company based in Toronto, Canada, focused on researching and developing novel therapeutics for various disease indications. Its lead drug candidate, ELND005, targets agitation and aggression associated with Alzheimer's disease and has completed Phase II/III clinical trials. The company is also advancing its metabolic drug candidate, TT401, which is currently undergoing Phase II clinical studies for the treatment of type 2 diabetes and obesity. Additionally, Transition is developing TT701, a selective androgen receptor modulator aimed at treating androgen deficiencies. The company has established a licensing and collaboration agreement with Eli Lilly to further develop TT401 and explore additional compounds that could offer glycemic control and weight loss benefits. Transition Therapeutics was founded in 1987 and originally named Transition Therapeutics and Diagnostics Inc., before rebranding in December 2000. As of August 2016, it operates as a subsidiary of Opko Health, Inc.
VBI Vaccines
Post in 2016
VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.
Arno Therapeutics
Post in 2016
Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.
Bio-Reference Laboratories
Acquisition in 2015
BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world.
EirGen Pharma
Acquisition in 2015
EirGen Pharma Ltd. is a pharmaceutical company based in Waterford, Ireland, specializing in the development, registration, and commercial manufacture of high potency solid dosage forms. Established in 2004, the company operates a state-of-the-art facility designed for the production of oncology, cytotoxic, steroidal, and immunosuppressant products, ensuring compliance with stringent safety standards. EirGen Pharma provides a range of services, including clinical trial management, drug formulation development, and contract manufacturing, catering to both human and veterinary markets. The company is fully licensed to manufacture and package investigational medicinal products and offers a variety of dosage forms such as film-coated tablets, soft-gel capsules, and powder or liquid-filled hard shells. EirGen Pharma serves clients across multiple regions, including the United States, Europe, Japan, Canada, Australia, the Middle East, and Africa. As of May 2015, it operates as a subsidiary of OPKO Ireland Limited.
Inspiro Medical
Acquisition in 2014
Inspiro Medical Ltd. is a medical device company focused on creating an advanced inhalation platform for the delivery of various therapeutic agents. This platform is designed to administer both small molecules, such as corticosteroids and beta agonists, as well as larger macromolecules, including antibodies and vaccines. The company is currently conducting clinical trials involving its proprietary dry powder inhaler, Inspiromatic, specifically targeting asthmatic children. Through its innovative approach, Inspiro Medical aims to enhance treatment options for patients with respiratory diseases.
PROLOR Biotech
Acquisition in 2013
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.
Cytochroma
Acquisition in 2013
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
FineTech Pharmaceutical
Acquisition in 2011
FineTech Laboratories specializes in the development and manufacturing of low volume, high value specialty active pharmaceutical ingredients (APIs). The company focuses on creating APIs through non-infringing processes and polymorphs, which allows it to navigate patent complexities effectively. FineTech's product portfolio includes notable compounds such as cabergoline, latanoprost, travoprost, nabilone, melatonin, and methylbenzethonium chloride. By offering a diverse range of APIs, FineTech Laboratories supports the healthcare sector in meeting its diverse needs and advancing pharmaceutical development.
Claros Diagnostics
Acquisition in 2011
Claros Diagnostics, Inc. develops innovative products aimed at transforming in-vitro medical diagnostic testing by making it accessible outside of laboratory settings. The company has created a handheld immunoassay system designed for point-of-care blood testing, which includes a portable analyzer and a disposable cassette capable of assessing multiple biomarkers. This system facilitates the testing of various medical conditions, including infectious diseases, cancer, and immune disorders, empowering both physicians and patients with timely diagnostic capabilities.
Fabrus
Venture Round in 2010
Fabrus LLC, founded in 2007 as the inaugural company in The Pfizer Incubator, specializes in therapeutic antibody discovery and development. The company has built a skilled scientific team that has successfully achieved key milestones through its innovative antibody discovery platform. This platform enables high-throughput identification of biologic lead candidates by facilitating direct screening for antibody leads on intact cells. Fabrus focuses on generating antibodies against challenging and therapeutically significant cell surface receptors, leveraging technologies such as ultralong CDR3 antibodies and the chimerasome nanocage. Through these advancements, Fabrus aims to discover multiple preclinical lead candidates targeting critical cancer indications.
Vidus Ocular
Acquisition in 2008
Vidus Ocular, Inc. develops an implantable physiologic device that is designed to address the shortcomings of glaucoma treatments. It offers Aquashunt, which is a shunt to treat glaucoma, the cause of blindness in the United States. The company is based in the United States. As of May 7, 2008, Vidus Ocular, Inc. operates as a subsidiary of Opko Health, Inc.
Acuity Pharmaceuticals
Acquisition in 2007
Acuity Pharmaceuticals is a pharmaceutical company based in Philadelphia, Pennsylvania, established in 2007. It specializes in the treatment and prevention of ophthalmic diseases, particularly focusing on age-related macular degeneration (AMD) and diabetic retinopathy (DR). The company is developing small interfering RNA compounds aimed at addressing vision loss associated with these conditions. One of its key products, Cand5, is a clinical compound designed to inhibit vascular endothelial growth factor, thereby targeting adult vision loss. In June 2011, Acuity Pharmaceuticals was acquired by OPKO Health, enhancing its capabilities in the ophthalmic market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.